Filter by: patients
What is Ergotamine and Caffeine?

Ergotamine tartrate is an antimigraine agent and caffeine is a stimulant. In combination they are used to treat or prevent vascular headaches, such as migraine, migraine variants, or so-called “histaminic cephalalgia”.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Cluster headaches 3 0
Migraine 2 1 Efficacy_none
Other 1 0

See all 4 patients currently taking Ergotamine and Caffeine

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
0
Moderate
0
Mild
0
None
1

Reported Dosages

  100mg-1mg as needed 100mg as needed 2 100mg-1mg as needed 2 x 100 mg-1 mg as needed
  1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Ergotamine and Caffeine (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 1   Did not seem to work: 25%
Expense 1   Expense: 25%
Personal research 1   Personal research: 25%
Doctor's advice 1   Doctor's advice: 25%
Other 1   Other: 25%
Course of treatment ended 1   Course of treatment ended: 25%

See all 4 patients who’ve stopped taking Ergotamine and Caffeine

Stopped Taking Ergotamine and Caffeine

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Ergotamine and Caffeine

Always
1 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Ergotamine and Caffeine

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
1 100%

Cost

Paid out of pocket

Cost of Ergotamine and Caffeine

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 27, 2012.